Henry Schein (NASDAQ:HSIC) and Scripsamerica (OTCMKTS:SCRCQ) Head-To-Head Analysis

Henry Schein (NASDAQ:HSIC) and Scripsamerica (OTCMKTS:SCRCQ) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Earnings & Valuation

This table compares Henry Schein and Scripsamerica”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Henry Schein	$12.67 billion	0.65	$390.00 million	$3.20	21.24
Scripsamerica	N/A	N/A	N/A	N/A	N/A

Henry Schein has higher revenue and earnings than Scripsamerica.

Profitability

This table compares Henry Schein and Scripsamerica’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Henry Schein	3.21%	14.87%	5.82%
Scripsamerica	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations for Henry Schein and Scripsamerica, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Henry Schein	0	8	4	0	2.33
Scripsamerica	0	0	0	0	0.00

Henry Schein presently has a consensus price target of $78.08, indicating a potential upside of 14.86%. Given Henry Schein’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Henry Schein is more favorable than Scripsamerica.

Insider & Institutional Ownership

96.6% of Henry Schein shares are held by institutional investors. 1.1% of Henry Schein shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Henry Schein beats Scripsamerica on 9 of the 9 factors compared between the two stocks.

About Henry Schein

Henry Schein, Inc. provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products, such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners; and value-added practice solutions comprising practice consultancy, education, revenue cycle management and financial services, e-services, practice technology, and network and hardware services, as well as consulting, and continuing education services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

About Scripsamerica

ScripsAmerica, Inc. develops and sells non-sterile topical and transdermal pain creams. The company also provides pharmacy dispensing services for individual doctors, as well as billing and administrative services to independent pharmacies. In addition, it distributes pharmaceutical products to independent pharmacies and other medical providers. The company was founded in 2008 and is based in Clifton, New Jersey. On February 8, 2017, the voluntary petition of ScripsAmerica, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on September 7, 2016.